The OS time was measured through Kaplan-Meier survival curve analysis and the results revealed that glioma patients with a low methylation level of SPRR3 had significantly lower progression-free survival rates (P=0.010) and OS times (P=0.007) than patients with a high methylation level. Here, SPRR3 is linked to glioma.